KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other financing activities: 2009-2024

Historic Other financing activities for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Dec 2024 value amounting to $2.0 million.

  • Rigel Pharmaceuticals' Other financing activities rose 2603.16% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 573.91%. This contributed to the annual value of $2.0 million for FY2024, which is 87.23% up from last year.
  • As of FY2024, Rigel Pharmaceuticals' Other financing activities stood at $2.0 million, which was up 87.23% from $1.0 million recorded in FY2023.
  • In the past 5 years, Rigel Pharmaceuticals' Other financing activities ranged from a high of $4.8 million in FY2021 and a low of $1.0 million during FY2023.
  • For the 3-year period, Rigel Pharmaceuticals' Other financing activities averaged around $1.7 million, with its median value being $2.0 million (2024).
  • Its Other financing activities has fluctuated over the past 5 years, first slumped by 55.52% in 2022, then spiked by 87.23% in 2024.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Other financing activities stood at $2.6 million in 2020, then surged by 83.94% to $4.8 million in 2021, then crashed by 55.52% to $2.1 million in 2022, then crashed by 50.61% to $1.0 million in 2023, then soared by 87.23% to $2.0 million in 2024.